Warfarin Self-Management in U.S. Health Care: Nonrandomized Trial

New studies support warfarin self-management in US healthcare systems. Self-management of warfarin by patients who measure and manage their own anticoagulation is receiving growing attention in the USA as a strategy to improve safety, access and patient engagement. A new nonrandomized trial published online in BMC Health Research in November 2017 evaluates the potential of PSM to improve patient management in routine practice.

Insights from the 2026 Implementation Trial

The 2026 implementation trial followed 120 patients with warfarin prescribed by 83 providers from four health care systems in the United States. The goal of this trial was to test the application of PSM in routine practice.

Why It Matters

There are many patients on warfarin for long periods of time and there is growing interest as to whether or not patients can safely manage their own anticoagulation. If done safely the biggest potential benefit of PSM is to improve the quality of anticoagulation and thus prevent thrombosis and severe bleeding. Patients on warfarin within a therapeutic range are less likely to experience a severe bleed. There is also potential cost savings of thousands of dollars per year per patient. The frequent monitoring required of a patient on warfarin is typically required and can be done by the patient instead of a provider in a clinic versus a laboratory.

What the Research Says:

1) Proven Feasibility and Superior Control

These studies demonstrated the efficacy of PSM in a variety of patient groups. The 2026 trial of PSM for warfarin in routine practice in the United States provides further evidence regarding the feasibility of PSM as well as providing data on patient-centered anticoagulation outcomes that are superior to those achieved in the current standard of care for even the “excellent” anticoagulation patient on warfarin. The percentage of time in therapeutic range (TTR) for even the best anticoagulation patients on warfarin at baseline increased significantly when they were transitioned to PSM (TTR increased from 77.1% to 81.3%, p < 0.001).

2) Patient Autonomy and Decision-Making

1) Patient Autonomy and Decision-Making: A High Level of Patient-Generated Information Supports Improved Anticoagulation.

• Dosing Independence: Participants made 83% of their warfarin dosing decisions independently, without contacting a clinician.
• Judgment over Tools: Interestingly, most patients (66.6%) relied on their own experience and judgment to adjust doses rather than using formal online dosing tools or manual algorithms.
• Clinician Safety Net: Despite this autonomy, clinicians remained a vital safety net by remotely reviewing every dosing decision recorded in electronic health records, though they rarely needed to intervene due to safety concerns.

3) Implementation Strategies: The “Spotters Ready” Phase

The ‘spotters ready’ phase: an important component of the implementation of PSM for warfarin patients. During this 2- to 4-week wash-in period, patients learn to interpret their INR results and make and implement warfarin dose changes independently. Health care providers review and give feedback on the patient’s proposed warfarin dose changes. Once patients have become competent to manage their warfarin independently, they take over all management of their warfarin.

4) Future Recommendations

Paying for a new system of management for patients on warfarin requires us to first understand the current system and then understand how the PSM model can add value. An initial way for health systems to begin to implement PSM is to start by recruiting and training a core group of patients on long-term warfarin who are currently stable on therapy and have excellent anticoagulation control. This group of patients would need to be very comfortable using a home monitor for INR testing. The best use of the resources of the anticoagulation clinics and pharmacies would be to develop an on-line education program that teaches these competent self-managers how to effectively manage their anticoagulation on their own. Health systems would then focus on the patients on warfarin who are at greatest risk for poor anticoagulation.

Implications for Clinicians and Healthsystems

Patients on long-term warfarin are the obvious group. That includes people with mechanical heart valves, certain types of artificial heart valves, some with antiphospholipid antibody syndrome, and others for whom newer direct oral anticoagulants are not appropriate. For these patients, maintaining the right INR is essential. Self-management gives motivated patients more control and can fit better with busy schedules, work, or remote living situations.

Implications for Payers and Hospitals

Many factors must be considered when a new program is being implemented in order to ensure that there is adequate implementation and follow-through to achieve good outcomes for patients and the health care system. First, the new program must result in better patient outcomes than are currently being achieved without increased cost. Many new models of chronic disease management have the potential to increase health care disparities if not implemented with consideration of access issues for all groups of patients. Finally, in order to implement a new program, many changes must be made in the daily functions of a variety of individuals and groups.

Who It Affects

Patients

Patients currently on long-term warfarin therapy for indications such as mechanical heart valves, other artificial heart valves, antiphospholipid antibody syndrome, and other indications for which the direct oral anticoagulants are not indicated. These patients are on long-term warfarin therapy and need on-going management of their warfarin therapy. Patients on long-term warfarin can greatly benefit from managing their warfarin therapy. These patients can be very motivated and can learn to monitor their INR and manage their warfarin independently. Patients on long-term warfarin are productive individuals. They have work, travel, and other activities and would like to be able to manage their warfarin therapy independently while at work, traveling, or living in remote locations.

Clinicians

Implications for Clinicians and Healthsystems. The same clinicians and the same systems of health care delivery can be used to manage patients on point of care INR who self manage as are used to manage today’s long term warfarin patients. Therefore, the same implications for all long term warfarin patients would apply to all patients on point of care INR who self manage as well. An important implication is that the distribution of clinical skills and the workflow in the clinic for management of patients on long term anticoagulation would not change for patients on point of care INR who self manage, compared to management of today’s long term warfarin patients. In addition, new roles of health care providers would be required to handle additional tasks for patients on point of care INR who self manage and tools and methods for management of patients in different clinical situations would be needed to safely manage these patients, to manage liability for these patients, and to improve the quality of their care.

Payers and Healthsystems

Payers. The initial costs of home INR monitoring devices and test strips are very expensive. However, in the long term these devices can save a lot of money by reducing the number of avoidable hospitalizations for stroke as well as for complications from bleeding. The Payers will need to weigh the short term costs against the long term savings in terms of avoided complications and reduced cost of care for these complications. Safety-net clinics as well as community organizations could consider the development of a program to lend home monitoring devices to patients that cannot afford to purchase the devices. In addition the organization could consider a program to provide free or low cost test strips to patients that cannot afford the test strips.

Policymakers

From a policy perspective, if medical device companies, health plans, and healthsystem regulators could develop clear reimbursement pathways for home monitoring devices and for telehealth, the model would expand rapidly to reach all patients for whom warfarin is indicated. For now, warfarin self-management is a program of choice for motivated patients with good support systems who have the resources to manage their chronic condition. The model can serve as a paradigm for efficient management of other chronic diseases, but it will require training of clinicians, and metrics for program evaluation.

What Changes

• Patients who are trained and supported can take daily responsibility for INR testing and dose decisions, shortening the lag between a lab result and a medication adjustment.
• Health systems may shift resources from routine monitoring visits to training, remote oversight, and targeted management of complex or unstable patients.
• Access and equity become central concerns. Programs that succeed will include financing options for devices, plain-language training, and technical support for people with limited health literacy or limited English proficiency.
• Regulatory and reimbursement policies will need to be updated. Coverage rules for home INR devices, telehealth oversight, and pharmacist-led management can make or break program viability.

Implementation in Practice

There are many different models of delivery of patient self-management of anticoagulation and how these are set up within an organization can vary widely. There are programs where patients test themselves using a portable INR monitor and then call in their result for the clinician to review and to issue a pre-determined dose of warfarin. This could be by telephone or by using a telehealth service and results reviewed on line by the clinician and a dose of warfarin issued as required. There are also very successful programs where patients receive hands-on training by a clinician or health care worker on how to use a home testing device and how to interpret their results. Patients who are managing their anticoagulation in this way are also able to manage and document any changes that they make to their warfarin dose. Importantly self-management of anticoagulation is not the same as self-prescribing and there are always safety-nets in place for patients managed through self-management of anticoagulation. These safety-nets would include for example: scheduled clinical review of the patient; emergency contacts as required; and thresholds that trigger a review by a clinician.

Barriers to Adoption

However, despite the good results of those in the trial there are also several potential barriers to the wider adoption of self-management.

• Age: Older patients were significantly less likely to volunteer for PSM, suggesting that age remains a primary factor in a patient’s willingness to take on the responsibility of self-management.
• Systemic Support: At the end of the study, while 84.4% of patients wanted to continue PSM, half of the participating sites lacked the formal policies or infrastructure to support the program beyond the research period.

Safety Concerns

Safety concerns with the use of patient-managed anticoagulated patients at home revolve around the risk of user error with several possible errors including: 1) inaccurate measurement of results from INR testing by the patient; 2) miscalculation of warfarin doses by the patient; and 3) failure of the patient or family to report completely all side effects to which the patient may be subject. To implement a safe warfarin self-management program, several layers of safety will need to be included. This would include a) multiple layers of training for the patient and their family members to manage anticoagulated health at home; b) monitoring for errors on the part of both the patient and the health care provider; and c) several safe mechanisms that would allow the patient to report any problems or have any questions and for these to be dealt with promptly. The patient for warfarin self-management will need to have the capacity to manage their anticoagulated health as a patient-managed anticoagulated patient at home.

Price Point Concerns

The cost of home testing devices for INR and test strips to be used with the meters to test patients’ blood can be very expensive. Often, Medicare and many commercial health plans will cover part of the cost of a home testing device for a patient on warfarin. However, there are many circumstances in which patients are expected to pay 100% of the cost of a home testing device for INR and test strips to go in the device on an ongoing basis. In some instances, however, pharmacy-based anticoagulation services lease out the devices to patients on warfarin. In addition, some employers and community organizations have established funds to help to pay for the cost of home testing for patients on warfarin.

Looking at warfarin self-management from a clinical decision-making perspective there are many more options for the patient rather than fewer. Direct oral anticoagulants have recently been introduced for certain clinical situations but there are many patients for whom warfarin is indicated and management of these patients on warfarin can be taken to a new level with warfarin self-management allowing for the most accurate management of the patient’s warfarin therapy in order to provide the patient with the very best of care. Decisions regarding patient management on warfarin will include consideration of the patient’s preference, the patient’s ability to manage their warfarin self-management, other clinical features of the patient, and the patient’s social circumstances.

Workforce Training: Downstream Implications

The training of the workforce is also crucial and involves nurses, pharmacists and community health workers, in clinics and in the community, who can coach, monitor, troubleshoot, and support patients, as well as make sure that the information technology systems used support this new management approach and securely transmit INR results and incorporate patients’ complete medical histories into their electronic health records, so that all of their healthcare providers can access this information.

Looking Ahead

However, technology for the management of anticoagulated patients will continue to evolve. The first aspect to look for in new meters is size and portability. The best new meters will be able to be easily carried in a patient’s pocket or purse and can be used in a variety of lighting conditions. Secondly, the best new meters will have sophisticated computer programs that will assist the patient and his or her health care providers in making the best warfarin dose for that patient on a given day. Some of these new meters will be able to track and remind patients of upcoming health care provider visits and for patients who are monitored by telehealth, the meter can alert health care providers to any abnormalities in INR results in a timely fashion. However, none of this technology will be of value unless there is adequate communication between patients and their health care providers and unless patients perceive that their health care providers trust them and are willing to allow them to self-manage on warfarin.

While Warfarin self-management is not the silver bullet for managing anticoagulated patients in chronic therapy, it holds much promise as a viable method for selected patients that can enhance their control of their therapy, decrease clinic time for health care providers and/or their staff and lead to improved patient outcomes. To make this a reality, however, the necessary resources must be devoted to ensure that health care systems have the training needed to establish and run these types of programs, all patients have access to necessary monitoring devices and that quality clinical management is provided on an on-going basis.

Reference

1. Witt DM, Hong H, Wilson AS, et al. Warfarin Patient Self-Management in the US Health Care System: A Nonrandomized Clinical Trial. JAMA Netw Open. 2026;9(3):e262627. Published 2026 Mar 2. doi:10.1001/jamanetworkopen.2026.2627